Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 414 participants.

Also called NCT01703221

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 414 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01703221
Main results
  • A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes Diabetes, obesity & metabolism, 2017-11 DOI, PubMed 28449368, PMC5655696 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01703221. Randomized; triple masking; primary purpose treatment. Start 2012-10-24 (actual); primary completion 2014-04-25 (actual). Results posted on 2015-10-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Omarigliptin
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Placebo to omarigliptin
Intervention (Drug)
Placebo to sitagliptin
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01703221
Content hash
af19ad26396fcb31c1afe218d46f38bf0d2344ba332a28ffe9f6e04ecb5208e4